Guinea vs United States: The number of people with susceptibility test result for rifampicin
Guinea
4,242
in 2021
United States
4,814
in 2021
Guinea rank
33rd
United States rank
30th
The number of people with susceptibility test result for rifampicin over time
- Guinea
- United States
How they compare
United States currently reports 4,814 against 4,242 in Guinea, a difference of 572.
That makes United States's figure about 1.1 times Guinea's.
Across all 5 years both countries report, United States has been ahead every year.
Guinea ranks 33rd and United States ranks 30th of 155 countries.
United States has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Guinea | United States | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,430 | 5,218 | 3,788 | United States |
| 2020s | 2,200 | 4,592 | 2,392 | United States |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Guinea or United States?
- United States, at 4,814 against 4,242 in Guinea as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Guinea and United States?
- 572, with United States ahead.
- How many years of comparable data are there for Guinea and United States?
- 5 years are reported by both, from 2017 to 2021.
- How do Guinea and United States rank globally for the number of people with susceptibility test result for rifampicin?
- Guinea ranks 33rd and United States ranks 30th of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.